Table 1 Baseline characteristics of the PCI + and PCI−/IHD− groups for the primary analysis
All patients (n = 3622) | Entire cohort | Propensity score-matched sample | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PCI+ (n = 564) | PCI−/IHD+ (n = 3058) | SD* | PCI+ (n = 489) | PCI−/IHD+ (n = 489) | SD* | |||||||
Age, mean ± standard deviance | 74 | ± 7.8 | 72 | ± 7.1 | 74 | ± 7.9 | 0.209 | 73 | ± 7.1 | 73 | ± 7.7 | 0.015 |
Sex | 0.231 | 0.035 | ||||||||||
Female | 785 | (22) | 80 | (14) | 705 | (23) | 74 | (15) | 68 | (14) | ||
Male | 2837 | (78) | 484 | (86) | 2353 | (77) | 415 | (85) | 421 | (86) | ||
Cancer type | ||||||||||||
Colorectal cancer | 1165 | (32) | 195 | (35) | 970 | (32) | 0.061 | 174 | (36) | 170 | (35) | 0.005 |
Lung cancer | 910 | (25) | 115 | (20) | 795 | (26) | 0.133 | 103 | (21) | 104 | (21) | 0.005 |
Prostate cancer | 505 | (14) | 124 | (22) | 381 | (12) | 0.254 | 97 | (20) | 98 | (20) | 0.010 |
Gastric cancer | 1042 | (29) | 130 | (23) | 912 | (30) | 0.154 | 115 | (23) | 117 | (24) | 0.080 |
Cancer stage | ||||||||||||
In situ | 252 | (7) | 48 | (9) | 204 | (7) | 0.070 | 45 | (9) | 41 | (8) | 0.016 |
Localised | 1836 | (51) | 297 | (53) | 1539 | (50) | 0.047 | 253 | (52) | 249 | (51) | 0.030 |
Regional to lymph nodes involved | 471 | (13) | 68 | (12) | 403 | (13) | 0.034 | 61 | (12) | 66 | (14) | 0.052 |
Regional by direct extension | 399 | (11) | 78 | (14) | 321 | (11) | 0.102 | 66 | (14) | 75 | (15) | 0.050 |
Distant site(s)/node(s) involved | 579 | (16) | 53 | (9) | 526 | (17) | 0.231 | 48 | (10) | 41 | (8) | 0.011 |
Unknown | 85 | (2) | 20 | (3) | 65 | (2) | 0.086 | 16 | (3) | 17 | (4) | 0.056 |
Barthel index score | ||||||||||||
60–100 | 3206 | (89) | 489 | (87) | 2717 | (89) | 0.066 | 428 | (87) | 427 | (87) | 0.006 |
40–59 | 153 | (4) | 21 | (3) | 132 | (4) | 0.030 | 19 | (4) | 15 | (3) | 0.045 |
0–39 | 263 | (7) | 54 | (10) | 209 | (7) | 0.100 | 42 | (9) | 47 | (10) | 0.035 |
Overweight | 968 | (27) | 164 | (29) | 804 | (27) | 0.069 | 144 | (29) | 148 | (30) | 0.018 |
Current or past smoking | 1986 | (55) | 328 | (58) | 1685 | (54) | 0.090 | 283 | (58) | 277 | (57) | 0.025 |
Dyslipidemia | 1052 | (29) | 323 | (57) | 729 | (24) | 0.740 | 259 | (53) | 252 | (52) | 0.029 |
Hypertension | 1851 | (51) | 384 | (69) | 1467 | (48) | 0.417 | 320 | (65) | 319 | (65) | 0.004 |
Diabetes mellitus | 1179 | (33) | 261 | (46) | 918 | (30) | 0.319 | 217 | (44) | 219 | (45) | 0.008 |
Chronic kidney disease | 252 | (7) | 47 | (9) | 205 | (7) | 0.068 | 44 | (9) | 49 | (10) | 0.035 |
Congestive heart failure | 635 | (18) | 168 | (30) | 467 | (15) | 0.343 | 133 | (27) | 148 | (30) | 0.068 |
Atrial fibrillation | 309 | (9) | 63 | (11) | 246 | (8) | 0.091 | 52 | (11) | 47 | (10) | 0.034 |
β-blocker | 2773 | (77) | 230 | (41) | 619 | (20) | 0.476 | 185 | (38) | 187 | (38) | 0.008 |
Statin | 2499 | (69) | 306 | (54) | 817 | (27) | 0.610 | 255 | (52) | 259 | (53) | 0.016 |
ACE inhibitor | 296 | (8) | 90 | (16) | 206 | (7) | 0.303 | 68 | (14) | 71 | (14) | 0.012 |
ARB | 1472 | (41) | 204 | (36) | 959 | (31) | 0.118 | 182 | (37) | 191 | (39) | 0.038 |
Oral anti-coagulants | 447 | (12) | 68 | (12) | 379 | (12) | 0.002 | 63 | (13) | 64 | (13) | 0.006 |
Acute coronary syndrome | 650 | (18) | 185 | (33) | 465 | (15) | 0.416 | 134 | (27) | 129 | (26) | 0.023 |
Days from cancer diagnosis to PCI/IHD admission, median (IQR) | 78 | (31–384) | 274 | (98–607) | 65 | (27–325) | 0.555 | 250 | (85–588) | 279 | (48–599) | 0.015 |
Chemo/radiation/hormonal therapy | 1242 | (34) | 168 | (30) | 1074 | (35) | 0.119 | 143 | (29) | 156 | (32) | 0.058 |
Surgery or endoscopic resection | 2300 | (64) | 369 | (65) | 1931 | (63) | 0.058 | 323 | (66) | 322 | (66) | 0.004 |